The British Pain Society updated their recommendations on intrathecal drug delivery (ITDD) for the management of pain and spasticity in adults. The recommendations are primarily evidence based but where necessary comprise the consensus opinion of the working group. The recommendations are accompanied by information for patients and their carers, intended to inform and support patients in their decision making. The updated guidance includes recent evidence base of ITDD use in pain and spasticity, address the issues of drug pump compatibility following the latest manufacturer and Medicines and Healthcare products Regulatory Agency (MHRA) recommendations as well as provide an update on the indications and complication management particularly endocrine complications and intrathecal granuloma formation.
PertCBSynderSH. Opioid receptor: demonstration in nervous tissue. Science1973; 179: 1947–1949.
2.
YakshTLRudyTA. Analgesia mediated by a direct spinal action of narcotics. Science1976; 192: 1357–1358.
3.
CousinsMJMatherLEGlynnCJ, et al.Selective spinal analgesia. Lancet1979; 1: 1141–1142.
4.
BeharMMagoraFOlshwangD, et al.Epidural morphine in treatment of pain. Lancet1979; 1: 527–529.
5.
WangJNaussLAThomasJE. Pain relief by intrathecally applied morphine in man. Anesthesiology1979; 50: 149–151.
6.
GourlayGKCherryDACousinsMJ. Cephalad migration of morphine in CSF following lumbar epidural administration in patients with cancer pain. Pain1985; 23: 317–326.
7.
DickensonAH. Recent advances in the physiology and pharmacology of pain: plasticity and its implications for clinical analgesia. J Psychopharmacol1991; 5: 342–351.
8.
TaylorAMcLeodG. Basic pharmacology of local anaesthetics. BJA Educ2020; 20: 34–41.
StaatsPSYearwoodTCharapataSG, et al.Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. JAMA2004; 291: 63–70.
11.
WermelingDDrassMEllisD, et al.Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol2003; 43: 624–636.
12.
WilliamsJELouwGTowlertonG. Intrathecal pumps for giving opioids in chronic pain: a systematic review. Health Technol Assess2000; 4(32): 1–65.
13.
TurnerJASearsJMLoeserJD. Programmable intrathecal opioid delivery systems for chronic noncancer pain: a systematic review of effectiveness and complications. Clin J Pain2007; 23(2): 180–195.
14.
PatelVBManchikantiLSinghV, et al.Systematic review of intrathecal infusion systems for long-term management of chronic non-cancer pain. Pain Physician2009; 12(2): 345–360.
15.
NobleMTreadwellJRTregearSJ, et al.Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev2010; 2010(1): CD006605.
16.
HayekSMDeerTRPopeJE, et al.Intrathecal therapy for cancer and non-cancer pain. Pain Physician2011; 14(3): 219–248.
17.
AtliATheodoreBRTurkDC, et al.Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. Pain Med2010; 11(7): 1010–1016.
18.
HamzaMDoleysDWellsM, et al.Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med2012; 13(10): 1304–1313.
19.
DuarteRVRaphaelJHSparkesE, et al.Long-term intrathecal drug administration for chronic non-malignant pain. J Neurosurg Anesthesiol2012; 24(1): 63–70.
20.
GriderJSEtscheidtMAHarnedME, et al.Trialing and maintenance dosing using a low-dose intrathecal opioid method for chronic nonmalignant pain: a prospective 36-month study. Neuromodulation2016; 19(2): 206–219.
21.
RaphaelJHDuarteRVSouthallJL, et al.Randomised, double-blind controlled trial by dose reduction of implanted intrathecal morphine delivery in chronic non-cancer pain. BMJ Open2013; 3(7): e003061.
22.
PopeJEJassalNSayedD, et al.A post-market, randomized, controlled, prospective study evaluating intrathecal pain medication versus conventional medical management in the non-cancer, refractory, chronic pain population (PROSPER). Expet Rev Med Dev2022; 19(11): 895–904.
23.
HaysRDSpritzerKLSchaletBD, et al.PROMIS®-29 v2.0 profile physical and mental health summary scores. Qual Life Res2018; 27(7): 1885–1891.
24.
ChapmanCRLipschitzDLAngstMS, et al.Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain2010; 11(9): 807–829.
25.
RauckRLWallaceMSLeongMS, et al.A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manag2006; 31(5): 393–406.
26.
WallaceMSCharapataSGFisherR, et al.Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation2006; 9(2): 75–86.
27.
DeerTRKimCBowmanR, et al.Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. Pain Physician2009; 12(4): E291–E296.
28.
WallaceMSKosekPSStaatsP, et al.Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med2008; 9(3): 271–281.
29.
WebsterLRFakataKLCharapataS, et al.Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. Pain Med2008; 9(3): 282–290.
30.
DeerTRauckRLKimP, et al.Effectiveness and safety of intrathecal ziconotide: interim analysis of the patient registry of intrathecal ziconotide management (PRIZM). Pain Pract2018; 18(2): 230–238.
31.
van RijnMAMuntsAGMarinusJ, et al.Intrathecal baclofen for dystonia of complex regional pain syndrome. Pain2009; 143(1-2): 41–47.
32.
van der PlasAAMarinusJEldabeS, et al.The lack of efficacy of different infusion rates of intrathecal baclofen in complex regional pain syndrome: a randomized, double-blind, crossover study. Pain Med2011; 12(3): 459–465.
33.
PerruchoudCEldabeSDurrerA, et al.Effects of flow rate modifications on reported analgesia and quality of life in chronic pain patients treated with continuous intrathecal drug therapy. Pain Med2011; 12(4): 571–576.
34.
EldabeSDuarteRVMadzingaG, et al.Comparison of the effects of intermittent boluses to simple continuous infusion on patients' global perceived effect in intrathecal therapy for pain: a randomized double-blind crossover study. Pain Med2017; 18(5): 924–931.
35.
BallantyneJCCarwoodCM. Comparative efficacy of epidural, subarachnoid and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev2005; 2005(1): CD005178.
36.
DuarteRCopleySNevittS, et al.Effectiveness and safety of intrathecal drug delivery systems for the management of cancer pain: a systematic review and meta-analysis. Neuromodulation2023; 26(6): 1126–1141.
37.
PerruchoudCDupoironDPapiB, et al.Management of cancer-related pain with intrathecal drug delivery: a systematic review and meta-analysis of clinical studies. Neuromodulation2023; 26(6): 1142–1152.
38.
Ontario Health. Intrathecal drug delivery systems for cancer pain: a health technology assessment. Ont Health Technol Assess Ser2024; 24(2): 161–162.
39.
SmithTJStaatsPSDeerT, et al.Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol2002; 20(19): 4040–4049.
40.
KenfieldMZachariasNAbd-ElsayedA. Intrathecal drug delivery for the treatment of cancer-associated chronic pain in children. Neuromodulation2023; 26(6): 1153–1163.
41.
SmithTJCoynePJStaatsPS, et al.An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol2005; 16(5): 825–833.
42.
SmithTJCoynePJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med2005; 8(4): 736–742.
43.
HamraJGYakshTL. Equianalgesic doses of subcutaneous but not intrathecal morphine alter phenotypic expression of cell surface markers and mitogen-induced proliferation in rat lymphocytes. Anesthesiology1996; 85(2): 355–365.
44.
StaatsPSYearwoodTCharapataSG, et al.Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS; a randomized controlled trial. JAMA2004; 291(1): 63–70.
45.
AlicinoIGiglioMMancaF, et al.Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice. Pain2012; 153(1): 245–249.
46.
DupoironDBoreFLefebvre-KuntzD, et al.Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. Pain Physician2012; 15(5): 395–403.
47.
PennRDSavoySMCorcosD, et al.Intrathecal baclofen for severe spinal spasticity. N Engl J Med1989; 320(23): 1517–1521.
48.
PennRD. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg1992; 77(2): 236–240.
49.
OchsGStrupplerAMeyersonBA, et al.Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study. J Neurol Neurosurg Psychiatry1989; 52(8): 933–939.
50.
LazorthesYSallerin–CauteBVerdieJC, et al.Chronic intrathecal baclofen administration for control of severe spasticity. J Neurosurg1990; 72(3): 393–402.
51.
LoubserPGNarayanRKSandinKJ, et al.Continuous infusion of intrathecal baclofen: long-term effects on spasticity in spinal cord injury. Paraplegia1991; 29(1): 48–64.
52.
CoffeyJRCahillDSteersW, et al.Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg1993; 78(2): 226–232.
53.
CreamerMCloudGKossmehlP, et al.Intrathecal baclofen therapy versus conventional medical management for severe poststroke spasticity: results from a multicentre, randomised, controlled, open-label trial (SISTERS). J Neurol Neurosurg Psychiatry2018; 89(6): 642–650.
54.
CreamerMCloudGKossmehlP, et al.Effect of intrathecal baclofen on pain and quality of life in poststroke spasticity. Stroke2018; 49(9): 2129–2137.
55.
de LissovoyGBrownREHalpernM, et al.Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome. Clin Therapeut1997; 19(1): 96–112.
56.
KumarKHunterGDemeriaDD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg2002; 97(4): 803–810.
57.
BiggsSADuarteRVRaphaelJH, et al.Influence of a latent period in QALY analysis: pilot study of intrathecal drug delivery systems for chronic non-malignant pain. Br J Neurosurg2011; 25(3): 401–406.
58.
KumarKRizviSBishopS. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. Clin J Pain2013; 29(2): 138–145.
59.
DuarteRVLambeTRaphaelJH, et al.Intrathecal drug delivery systems for the management of chronic noncancer pain: a systematic review of economic evaluations. Pain Pract2018; 18(5): 666–686.
60.
DewildeSVerdianLMaclaineGD. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin2009; 25(8): 2007–2019.
61.
LambeTDuarteREldabeR, et al.Ziconotide for the management of cancer pain: a budget impact analysis. Neuromodulation2023; 26: 1226–1232.
62.
HassenbuschSJPaiceJAPattRB, et al.Clinical realities and economic considerations: economics of intrathecal therapy. J Pain Symptom Manag1997; 14(3): S36–S48.
63.
Mueller-SchwefeGHassenbuschSJReigE. Cost effectiveness of intrathecal therapy for pain. Neuromodulation1999; 2(2): 77–87.
64.
StearnsLJHinnenthalJAHammondK, et al.Health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management. Neuromodulation2016; 19(2): 196–205.
65.
StearnsLJNarangSAlbrightRE, et al.Assessment of health care utilization and cost of targeted drug delivery and conventional medical management vs conventional medical management alone for patients with cancer-related pain. JAMA Netw Open2019; 2(4): e191549.
66.
SampsonFCHaywardAEvansG, et al.Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity. J Neurosurg2002; 96(6): 1052–1057.
67.
de LissovoyGMatzaLSGreenH, et al.Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy. J Child Neurol2007; 22(1): 49–59.
68.
BensmailDWardABWisselJ, et al.Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticity. Neurorehabilitation Neural Repair2009; 23(6): 546–552.
NHS England. Clinical commissioning policy: intrathecal pumps for treatment of severe cancer pain. UK: NHS England, 2015.
71.
GoudmanLDe SmedtAHuygensR, et al.Hospital at home for intrathecal pump refills: a prospective effectiveness, safety and feasibility study. J Clin Med2021; 10(22): 5353.
72.
BarkerFGIICurryWTCarterBS. Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider caseload and centralization of care. Neuro Oncol2005; 7(1): 49–63.
73.
SmithERButlerWEBarkerFG2nd. Craniotomy for resection of pediatric brain tumors in the United States, 1988 to 2000: effects of provider caseloads and progressive centralization and specialization of care. Neurosurgery2004; 54(3): 553–563.
74.
SmithERButlerWEBarkerFG2nd. In-hospital mortality rates after ventriculoperitoneal shunt procedures in the United States, 1998 to 2000: relation to hospital and surgeon volume of care. J Neurosurg2004; 100(2): 90–97.
75.
MikeBKarenSAssociation for Palliative Medicine (APM) The Pain Society. The use of drugs beyond licence in palliative care and pain management, The British Pain Society2005; 16(5): 367–368.
76.
RaphaelJHSouthallJLGnanaduraiTV, et al.Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain. BMC Muscoskel Disord2002; 3(1): 17–25.
77.
RaphaelJHSouthallJLGnanaduraiTV, et al.Multiple lead spinal cord stimulation for chronic mechanical low back pain: a comparative study with intrathecal opioid drug delivery. Neuromodulation2004; 7(4): 260–266.
78.
IliasWle PolainBBuchserE, et al.Patient-controlled analgesia in chronic pain patients: experience with a new device designed to be used with implanted programmable pumps. Pain Pract2008; 8: 164–170.
79.
PengPWFedoroffIJacquesL, et al.Survey of the practice of spinal cord stimulators and intrathecal analgesic delivery implants for management of pain in Canada. Pain Res Manag2007; 12: 281–285.
80.
van HiltenBJvan de BeekWJHoffJI, et al.Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med2000; 343(9): 625–630.
81.
ShaladiASaltariMRPivaB, et al.Continuous intrathecal morphine infusion in patients with vertebral fractures due to osteoporosis. Clin J Pain2007; 23(6): 511–517.
82.
BroseWGGutloveDPLutherRR, et al.Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain1997; 13(3): 256–259.
83.
De AndresJPerottiLPalmisaniS, et al.Chronic pain due to postsurgical intra- abdominal adhesions: therapeutic options. In: KapuralL (ed). Chronic Abdominal Pain: An Evidence-Based, Comprehensive Guide to Clinical Management. New York: Springer, 2014, pp. 77–88.
84.
DoleysDM. Preparing pain patients for implantable technologies. In: TurkDCGatchelRJ (eds). Psychological approaches to pain management 2002. 2nd ed.New York: Guilford, 2002, pp. 334–348.
85.
AndersonVCBurchielKJCookeB. A prospective, randomized trial of intrathecal injection vs. epidural infusion in the selection of patients for continuous intrathecal opioid therapy. Neuromodulation2003; 6(3): 142–152.
86.
DominguezESahinlerBBassamD, et al.Predictive value of intrathecal narcotic trials for long-term therapy with implantable drug administration systems in chronic non-cancer pain patients. Pain Pract2002; 2(4): 315–325.
87.
GalicaRJHayekSMVeiziE, et al.Intrathecal trialing of continuous infusion combination therapy with hydromorphone and bupivacaine in failed back surgery patients. Neuromodulation2018; 21(7): 648–654.
88.
GrondSZechDSchugSA, et al.Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manag1991; 6(7): 411–422.
89.
ZechDFGrondSLynchJ, et al.Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain1995; 63(1): 65–76.
90.
StjernswardJColleauSMVentafriddaV. The world health organisation cancer pain and palliative care program: past, present and future. J Pain Symptom Manag1996; 12(2): 65–72.
91.
DupoironDDuarteRCarvajalG, et al.Rationale and recent advances in targeted drug delivery for cancer pain: is it time to change the paradigm?Pain Physician2022; 25(3): E414–E425.
92.
ChapmanEJEdwardsZBolandJW, et al.Practice review: evidence-Based and effective management of pain in patients with advanced cancer. Palliat Med2020; 34(4): 444–453.
93.
HanksGWCoonFChernyN, et al.Expert working group of the research network of the European association of palliative care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer2001; 84: 587–593.
94.
RaphaelJAhmedzaiSHesterJ, et al.Cancer pain: part 1: pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British pain society endorsed by the UK association of palliative medicine and the royal college of general practitioners. Pain Med2010; 11(5): 742–764.
95.
RaphaelJHesterJAhmedzaiS, et al.Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. Pain Med2010; 11(6): 872–896.
96.
DahmPNitescuPApplegrenL, et al.Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and/or bupivacaine in refractory non malignant pain; a comparison between the epidural and intrathecal approach with externalized or implanted catheters and infusion pimps. Clin J Pain1998; 14: 4–16.
97.
MercadanteS. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain1999; 79: 1–13.
98.
BakerLLeeMRegnardC, et al.Evolving spinal analgesia practice in palliative care. Palliat Med2004; 18: 507–515.
99.
GestinYVainioAPégurierAM. Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol Scand1997; 41: 12–17.
100.
SjobergMKarlssonPANordborgC, et al.Neuropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients. Anaesthesiology1992; 76(2): 173–186.
101.
PennRDPaiceJAGottschalkW, et al.Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. J Neurosurg1984; 61: 302–306.
102.
DuarteRVSaleADesaiP, et al.The unmet need for intrathecal drug delivery pumps for the treatment of cancer pain in England: an assessment of the hospital episode statistics database. Neuromodulation2020; 23(7): 1029–1033.
103.
DupoironDRichardHChabert-DesnotV, et al.In vitro stability of low-concentration ziconotide alone or in admixtures in intrathecal pumps. Neuromodulation2014; 17(5): 472–482.
104.
RobertJSorrieulJDupoironD, et al.Physicochemical stability study of the morphine-ropivacaine-ziconotide association in implantable pumps for intrathecal administration. Neuromodulation2023; 26(6): 1179–1194.
105.
SorrieulJRobertJVincentL, et al.Stability of morphine sulfate-clonidine and sufentanil-clonidine mixtures. Neuromodulation2023; 26(6): 1195–1207.
106.
CoiaJEDuckworthGJEdwardsDI, et al.Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect2006; 63: S1–S44.
107.
ScanlonMMGazelkaHMMoeschlerSM, et al.Surgical site infections in cancer patients with intrathecal drug delivery devices. Pain Med2017; 18(3): 520–525.
108.
HorlockerTT. Regional anaesthesia in the patient receiving antithrombic and antiplatelets therapy. Br J Anaesth2011; 107: i96–i106.
109.
AbsRVerhelstJMaeyaertJ, et al.Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab2000; 85(6): 2215–2222.
110.
DuarteRVRaphaelJHLabibM, et al.Prevalence and influence of diagnostic criteria in the assessment of hypogonadism in intrathecal opioid therapy patients. Pain Physician2013; 16(1): 9–14.
111.
DuarteRVRaphaelJHSouthallJL, et al.Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy. BMJ Open2013; 3(6): e002856.
112.
FinchPMPriceLMPullanPT, et al.Effects of testosterone treatment on bone mineral density in hypogonadal men receiving intrathecal opioids. Pain Pract2015; 15: 308–313.
113.
DuPenSLPetersonDGBogosianAC, et al.A new permanent exteriorized epidural catheter for narcotic self-administration to control cancer pain. Cancer1987; 59: 986–993.
114.
GradyKRaphaelJ. Spinal administration. In: RiceA (ed). Textbook of Clinical Pain Management: Chronic volume. London: Hodder Arnold, 2008, pp. 284–291.
115.
DarouicheRO. Treatment of infections associated with surgical implants. N Engl J Med2004; 350(14): 1422–1429.
116.
FollettKABoortz-MarxRLDrakeJM, et al.Prevention and management of intrathecal drug delivery and spinal cord stimulation system infections. Anesthesiology2004; 100: 1582–1594.
117.
Da CostaAKirkorianGCucheratM, et al.Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation1998; 97(18): 1796–1801.
118.
PaiceJAPennRDShottS. Intraspinal morphine for chronic pain: a retrospective, multicenter study. J Pain Symptom Manag1996; 11: 71–80.
119.
FeldenLWalterCHarderS, et al.Comparative clinical effects of hydromorphone and morphine: a meta-analysis. Br J Anaesth2011; 107(3): 319–328.
120.
AdeTRohJSharmaG, et al.Comparative effectiveness of targeted intrathecal drug delivery using a combination of bupivacaine with either low-dose fentanyl or hydromorphone in chronic back pain patients with lumbar postlaminectomy syndrome. Pain Med2020; 21(9): 1921–1928.
121.
RaphaelJHPalfreySMRayenA, et al.Stability and analgesic efficacy of Diacetyl Morphine (Diamorphine) compared with morphine in implanted intrathecal pumps in Vivo. Neuromodulation2004; 7: 197–200.
122.
SimpsonKH. Report from a meeting to consider the use of diamorhphine in totally implantable intrathecal pumps. UK: The British Pain Society Newsletter, 2004, pp. 10–12.
123.
GregoryMABrock-UtneJGBuxS, et al.Morphine concentration in brain and spinal cord after subarachnoid morphine injection in baboons. Anesth Analg1985; 64: 929–932.
124.
AndersonVCBurchielKJ. A prospective study of long-term Intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery1999; 44(2): 289–300.
125.
PetakSMNankinHRSparkRF, et al.American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients - 2002 update. Endocr Pract2002; 8(6): 440–456.
126.
DoleysDDinoffBPageL, et al.Sexual dysfunction and other side effects of intraspinal opiate use in the management of chronic non-cancer pain. Am J Pain Manag1998; 8(1): 5–11.
127.
KatzNMazerNA. The impact of opioids on the endocrine system. Clin J Pain2009; 25(2): 170–175.
128.
KatznelsonLFinkelsteinJSSchoenfeldDA, et al.Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab1996; 81(12): 4358–4365.
129.
DuarteRVRaphaelJHSouthallJL, et al.Intrathecal inflammatory masses: is the yearly opioid dose increase an early indicator?Neuromodulation2010; 13(2): 109–113.
130.
YakshTLHassenbuschSBurchielK, et al.Inflammatory masses associated with intrathecal drug infusion: a review of preclinical evidence and human data. Pain Med2002; 3(4): 300–312.
131.
YakshTLAllenJWVeesartSL, et al.Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation. Anesthesiology2013; 118(3): 664–678.
132.
BloomfieldSHoggJOrtizO, et al.Analysis of breakthrough pain in 50 patients treated with intrathecal morphine infusion therapy. Development of tolerance or infusion system malfunction. Stereotact Funct Neurosurg1995; 65(1-4): 142–146.
133.
AndersonSROrbegozoMRaczG, et al.Intrathecal granuloma in patients receiving high-dose intrathecal morphine therapy: a report of two cases. Pain Pract2001; 1(1): 61–67.
134.
BejjaniGKKarimNOTzortzidisF. Intrathecal granuloma after implantation of a morphine pump: case report and review of the literature. Surg Neurol1997; 48(3): 288–291.
135.
LehmbergJScheiweCSpreerJ, et al.Late bacterial granuloma at an intrathecal drug delivery catheter. Acta Neurochir2006; 148(8): 899–901.
136.
NarouzeSNCasanovaJSouzdalnitskiD. Patients with a history of spine surgery or spinal injury may have a higher chance of intrathecal catheter granuloma formation. Pain Pract2014; 14(1): 57–63.
137.
LangsamA. A case of spinal cord compression syndrome by a fibrotic mass presenting in a patient with an intrathecal pain management pump system. Pain1999; 83(1): 97–99.
138.
NorthRBCutchisPNEpsteinJA, et al.Spinal cord compression complicating subarachnoid infusion of morphine: case report and laboratory experience. Neurosurgery1991; 29(5): 778–784.
139.
RamseyCNOwenRDWittWO, et al.Intrathecal granuloma in a patient receiving high dose hydromorphone. Pain Physician2008; 11(3): 369–373.
140.
MutagiHChavanSKapurS, et al.First report of diamorphine associated intrathecal catheter-tip granuloma. Reg Anesth Pain Med2007; 32(5): 67.
De AndrésJTatay VivòJPalmisaniS, et al.Intrathecal granuloma formation in a patient receiving long-term spinal infusion of tramadol. Pain Med2010; 11(7): 1059–1062.
143.
DeerTRRasoLJGartenTG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med2007; 8(3): 259–262.
144.
MurphyPMSkouvaklisDEAmadeoRJ, et al.Intrathecal catheter granuloma associated with isolated baclofen infusion. Anesth Analg2006; 102(3): 848–852.
145.
ZacestACCarlsonJDNemecekA, et al.Surgical management of spinal catheter granulomas: operative nuances and review of the surgical literature. Neurosurgery2009; 65(6): 1161–1164.
146.
VeiziIEHayekSMHanesM, et al.Primary hydromorphone-related intrathecal catheter tip granulomas: is there a role for dose and concentration?Neuromodulation2016; 19(7): 760–769.
DuarteRVRaphaelJHSouthallJL, et al.Intrathecal granuloma formation as result of opioid delivery: systematic literature review of case reports and analysis against a control group. Clin Neurol Neurosurg2012; 114(6): 577–584.
149.
YakshTLHoraisKATozierNA, et al.Chronically infused intrathecal morphine in dogs. Anesthesiology2003; 99(1): 174–187.
150.
FlackSHAndersonCMBernardsC. Morphine distribution in the spinal cord after chronic infusion in pigs. Anesth Analg2011; 112(2): 460–464.
151.
PageLHildebrandKBillstromT, et al.Effect of intrathecal intermittent boluses and morphine concentration on the incidence of inflammatory mass in a canine model. Neuromodulation2013; 16(5): e94.
152.
HildebrandKRPageLMBillstromTM, et al.Characterization of effect of repeated bolus or continuous intrathecal infusion of morphine on spinal mass formation in the dog. Neuromodulation2019; 22(7): 790–798.
153.
LangsamA. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery1999; 44(3): 689–691.
154.
DeerTRPragerJLevyR, et al.Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation2012; 15(5): 483–495.
155.
CabbellKLTarenJASagherO. Spinal cord compression by catheter granulomas in high-dose intrathecal morphine therapy: case report. Neurosurgery1998; 42(5): 1176–1180.
156.
ShieldsDPalmaCKhooL, et al.Extramedullary intrathecal catheter granuloma adherent to the conus medullaris presenting as cauda equina syndrome. Anesthesiology2005; 102(5): 1059–1061.
157.
ToombsJFollettKRosenquistR, et al.Intrathecal catheter tip inflammatory mass: a failure of clonidine to protect. Anesthesiology2005; 102(3): 687–690.
158.
De AndrésJPalmisaniSVillanueva PérezVL, et al.Can an intrathecal, catheter-tip-associated inflammatory mass reoccur?Clin J Pain2010b; 26(7): 631–634.
159.
HoederathPGautschiOPLandM, et al.Formation of two consecutive intrathecal catheter tip granulomas within nine months. Cent Eur Neurosurg2010; 71(1): 39–42.
160.
BlountJRemleyKYueS, et al.Intrathecal granuloma complicating chronic spinal infusion of morphine. Report of three cases. J Neurosurg1996; 84: 272–276.
161.
StaatsPSMitchellVD. Future directions for intrathecal therapies. Prog Anesthesiol1997; 11: 367–382.
162.
BerdeCBSethnaNFConradLS, et al.Subarachnoid bupivacaine analgesia for seven months for a patient with a spinal cord tumor. Anesthesiology1990; 72: 1094–1096.
163.
DahmPNitescuPAppelgrenL, et al.Continuous intrathecal infusion of opioid and bupivacaine in the treatment of refractory pain due to postherpetic neuralgia: a case report. Neuromodulation1998; 1: 85–89.
164.
KramesESLanningRM. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manag1993; 8: 539–548.
165.
van DongenRTCrulBJvan EgmondJ. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain1999; 15(3): 166–172.
166.
SjobergMNitescuPAppelgrenL, et al.Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology (Hagerst)1994; 80(2): 284–297.
EisenachJCDu PenSDuboisM, et al.Epidural Clonidine analgesia for intractable cancer pain. Pain1995; 61: 391–399.
169.
CoombsDWSaundersRLLachanceD, et al.Intrathecal morphine tolerance: use of intrathecal Clonidine, DADLE, and intraventricular morphine. Anesthesiology1985; 62: 358–363.
170.
CoombsDWSaundersRLFratkinJD, et al.Continuous intrathecal hydromorphone and Clonidine for intractable cancer pain. J Neurosurg1986; 64: 890–894.
171.
SiddallPJGrayMRutkowskiS, et al.Intrathecal morphine and Clonidine in the management of spinal cord injury pain: a case report. Pain1994; 59: 147–148.
172.
TairaTKawamuraHTanikawaT, et al.A new approach to control central deafferentation pain: spinal intrathecal baclofen. Sterotact Funct Neurosurg1995; 65: 101–105.
173.
ZunigaRESchlichtCRAbramSE. Intrathecal baclofen is analgesic in patients with chronic pain. Anesthesiology2000; 92: 876–880.
174.
BowersoxSSGadboisTSinghT, et al.Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent, and neuropathic pain. J Pharmacol Exp Therapeut1996; 279: 1243–1249.
DeerTKramesESHassenbuschSJ, et al.Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation2007; 10(4): 300–328.
177.
MatisGDe NegriPDupoironD, et al.Intrathecal pain management with ziconotide: time for consensus?Brain Behav2021; 11(1): e02055.
178.
ShieldsDMontenegroRRagusaM. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation2005; 8(4): 257–263.
179.
ShieldsDMontenegroRAclanJ. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation2007; 10(1): 12–17.
180.
ShieldsDMontenegroR. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation2007; 10(1): 6–11.
181.
HildebrandKRElsberryDDDeerTR. Stability, compatibility, and safety of intrathecal bupivacaine administered chronically via an implantable delivery system. Clin J Pain2001; 17: 239–244.
182.
HildebrandKRElsberryDEAndersonVC. Stability and compatibility of hydromorphone in an implantable infusion system. J Pain Symptom Manag2001; 22: 1045–1047.
183.
RudichZPengPDunnE, et al.Stability of clonidine in clonidine hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manag2004; 28: 599–602.
184.
ClassenAMWimbishGHKupiecTC. Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manag2004; 28: 603–611.
185.
WulfHGleimMMignatC. The stability of mixtures of morphine hydrochloride, bupivacaine hydrochloride and clonidine hydrochloride in portable pump reservoirs for the management of chronic pain syndromes. J Pain Symptom Manag1994; 9: 308–311.
186.
CopleySYassaPEBatterhamAM, et al.A clinical evaluation of the accuracy of an intrathecal drug delivery device. Neuromodulation2023; 26(6): 1240–1246.
187.
AlvarezJ-CDe MazancourtPChartier-KastlerE, et al.Drug stability testing to support clinical feasibility investigations for intrathecal baclofen-clonidine admixture. J Pain Symptom Manag2004; 28(3): 268–272.
188.
BazinCPoirierA-LDupoironD. Influence of pH and temperature on ziconotide stability in intrathecal analgesic admixtures in implantable pumps and syringes. Int J Pharm2015; 487(1-2): 285–291.
189.
BianchiFGinggenATardyY. Stability and compatibility of drug mixtures in an implantable infusion system. Anaesthesia2008; 63(9): 972–978.
190.
GouckeCRDusciLJVan LeeuwenS, et al.Stability and tolerability of high concentrations of intrathecal bupivacaine and opioid mixtures in chronic noncancer pain: an open-label pilot study. Pain Med2010; 11(11): 1612–1618.
191.
HildebrandKRElsberryDDHassenbuschSJ. Stability and compatibility of morphine-clonidine admixtures in an implantable infusion system. J Pain Symptom Manag2003; 25(5): 464–471.
192.
MacorighCGuibbertVCasanovaM, et al.Stability study of hydromorphone and bupivacaine mixture by HPLC-UV. Eur J Hosp Pharm2020; 27(2): 95–99.
193.
RudichZPengPDunnE, et al.Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manag2004; 28(6): 599–602.
194.
ShieldsDEAclanJSzatkowskiA. Chemical stability of admixtures containing ziconotide 25 mcg/mL and morphine sulfate 10 mg/mL or 20 mg/mL during simulated intrathecal administration. Int J Pharm Compd2008; 12(6): 553–557.
195.
DuarteRVRaphaelJHHaqueMS, et al.A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. Pain Physician2012; 15(5): 363–369.
196.
HamzaMDoleysDWellsM, et al.Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Med2012; 13(10): 1304–1313.
197.
van DongenRTCrulBJDe BockM. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain1993; 55(1): 119–123.
198.
VeiziIEHayekSMNarouzeS, et al.Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients. Pain Med2011; 12(10): 1481–1489.
199.
HayekSMVeiziIENarouzeSN, et al.Age-dependent intrathecal opioid escalation in chronic noncancer pain patients. Pain Med2011; 12(8): 1179–1189.
GhafoorVLEpshteynMCarlsonGH, et al.Intrathecal drug therapy for long-term pain management. Am J Health Syst Pharm2007; 64(23): 2447–2461.
202.
DeerTRPopeJEHayekS, et al.The polyanalgesic consensus conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation2017; 20(2): 96–132.
203.
DeerTRHayekSMGriderJS, et al.The polyanalgesic consensus conference (PACC)®: intrathecal drug delivery guidance on safety and therapy optimization when treating chronic noncancer pain. Neuromodulation, 2024. in press. doi: 10.1016/j.neurom.2024.03.003.
204.
FollettKANaumannCP. A prospective study of catheter-related complications of intrathecal drug delivery systems. J Pain Symptom Manag2000; 19: 209–215.
205.
CoffeyRJOwensMLBrosteSK, et al.Mortality associated with implantation and management of intrathecal opioid drug infusion systems to treat noncancer pain. Anesthesiology2009; 111(4): 881–891.
206.
CoffeyRJOwensMLBrosteSK, et al.Medical practice perspective: identification and mitigation of risk factors for mortality associated with intrathecal opioids for non-cancer pain. Pain Med2010; 11(7): 1001–1009.
207.
DeerTRPragerJLevyR, et al.Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation2012; 15(5): 436–464.
208.
RiglerMLDrasnerKKrejcieTC, et al.Cauda equina syndrome after continuous spinal anesthesia. Anesth Analg1991; 72(3): 275–281.
209.
DevulderJGhysLDhondtW, et al.Spinal analgesia in terminal care; risk versus benefit. J Pain Symptom Manag1994; 9: 75–81.
210.
ByersKAxlerodPMichaelS, et al.Infections complicating tunnelled intraspinal catheter systems used to treat chronic pain. Clin Infect Dis1995; 21: 403–408.
211.
DeerTRLevyRPragerJ, et al.Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation2012; 15(5): 467–482.
212.
MalheiroLGomesABarbosaP, et al.Infectious complications of intrathecal drug administration systems for spasticity and chronic pain: 145 patients from a tertiary care center. Neuromodulation2015; 18(5): 421–427.
213.
ApplegrenLNordborgCSjobergM, et al.Spinal epidural metastasis: implications for spinal analgesia to treat ‘refractory’ cancer pain. J Pain Symptom Manag1997; 13: 25–42.
214.
ChrubasikJChrubasikSMartinE. Patient-controlled spinal opiate analgesia in terminal cancer. Has its time really arrived?Drugs1992; 43(6): 799–804.
